Paper22825331
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Prevo R and 7 others. Cancer Biol Ther, 2012. Cited by 200 papers, by iCite.
Cite this record
ConductScience Library. The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy. Papers, record 22825331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22825331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Deoxycytidine | Major topic |
| Pancreatic Neoplasms | Major topic |
| Pyrazines | Major topic |
| Sulfones | Major topic |
| Ataxia Telangiectasia Mutated Proteins | |
| Cell Cycle Checkpoints | |
| Cell Cycle Proteins | |
| Cell Hypoxia | |
| Cell Line, Tumor | |
| Combined Modality Therapy | |
| DNA Damage | |
| DNA Repair | |
| Humans | |
| Phosphorylation | |
| Protein Serine-Threonine Kinases | |
| Radiation-Sensitizing Agents | |
| Signal Transduction | |
| Gemcitabine |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 11563 | Cancer Research UK | United Kingdom | PubMed | |
| G0700730 | Medical Research Council | United Kingdom | PubMed |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 41412153 | Correction. | https://conductscience.org/library/papers/41412153 |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11072146 | Pancreatic tumors show high levels of hypoxia. | Int J Radiat Oncol Biol Phys | 2000 | https://conductscience.org/library/papers/11072146 | PubMed |
| 2 | 20606093 | Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/20606093 | PubMed |
| 3 | 19718024 | Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. | Nat Genet | 2009 | https://conductscience.org/library/papers/19718024 | PubMed |
| 4 | 21820372 | Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. | Mol Oncol | 2011 | https://conductscience.org/library/papers/21820372 | PubMed |
| 5 | 15084616 | Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. | J Clin Oncol | 2004 | https://conductscience.org/library/papers/15084616 | PubMed |
| 6 | 18256616 | DNA repair pathways as targets for cancer therapy. | Nat Rev Cancer | 2008 | https://conductscience.org/library/papers/18256616 | PubMed |
| 7 | 11481349 | Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. | J Clin Oncol | 2001 | https://conductscience.org/library/papers/11481349 | PubMed |
| 8 | 20501833 | Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. | Cancer Res | 2010 | https://conductscience.org/library/papers/20501833 | PubMed |
| 9 | 16648548 | Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. | Mol Cancer Ther | 2006 | https://conductscience.org/library/papers/16648548 | PubMed |
| 10 | 15073105 | Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. | Clin Cancer Res | 2004 | https://conductscience.org/library/papers/15073105 | PubMed |
| 11 | 20615227 | The role of radiotherapy in multimodal treatment of pancreatic carcinoma. | Radiat Oncol | 2010 | https://conductscience.org/library/papers/20615227 | PubMed |
| 12 | 21430696 | Strategies to improve radiotherapy with targeted drugs. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21430696 | PubMed |
| 13 | 19305158 | Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. | Cell Cycle | 2009 | https://conductscience.org/library/papers/19305158 | PubMed |
| 14 | 18632646 | Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. | Cancer Res | 2008 | https://conductscience.org/library/papers/18632646 | PubMed |
| 15 | 21306953 | Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. | Lancet Oncol | 2011 | https://conductscience.org/library/papers/21306953 | PubMed |
| 16 | 21255190 | Hypoglycemic/hypoxic condition in vitro mimicking the tumor microenvironment markedly reduced the efficacy of anticancer drugs. | Cancer Sci | 2011 | https://conductscience.org/library/papers/21255190 | PubMed |
| 17 | 22120667 | Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. | Nat Struct Mol Biol | 2011 | https://conductscience.org/library/papers/22120667 | PubMed |
| 18 | 19806144 | Epidemiology of pancreatic cancer: an overview. | Nat Rev Gastroenterol Hepatol | 2009 | https://conductscience.org/library/papers/19806144 | PubMed |
| 19 | 17452677 | Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17452677 | PubMed |
| 20 | 21730979 | Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. | Br J Cancer | 2011 | https://conductscience.org/library/papers/21730979 | PubMed |
Cited by132
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 200 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42980881 | Quantitative systems pharmacology modeling identifies synthetic lethality opportunities with DNA damage response inhibitors in ATM-deficient chronic lymphocytic leukemia - a computational simulation study. | J Pharmacokinet Pharmacodyn | 2026 | https://conductscience.org/library/papers/42980881 | PubMed |
| 42376674 | DNA damage response inhibitors in pancreatic cancer: progress and challenges. | Front Oncol | 2026 | https://conductscience.org/library/papers/42376674 | PubMed |
| 42244588 | Transient ATR inhibition following ionizing radiation enhances immune-mediated antitumor response and survival. | bioRxiv | 2026 | https://conductscience.org/library/papers/42244588 | PubMed |
| 42082831 | Succinate dehydrogenase loss suppresses pyrimidine biosynthesis via succinate-mediated inhibition of aspartate transcarbamylase. | Nat Metab | 2026 | https://conductscience.org/library/papers/42082831 | PubMed |
| 41787655 | Inhibition of Autophagy Reveals ATR Protein Kinase as a Key Mediator of Cisplatin Sensitivity in Osteosarcoma. | Cancer Med | 2026 | https://conductscience.org/library/papers/41787655 | PubMed |
| 41614897 | Replication Stress in Cancer: Mechanistic Insights and Therapeutic Opportunities for Radiosensitization. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/41614897 | PubMed |
| 41575477 | Palladium-catalyzed Suzuki-Miyaura and Buchwald-Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules. | Mol Divers | 2026 | https://conductscience.org/library/papers/41575477 | PubMed |
| 41563386 | Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/41563386 | PubMed |
| 41120356 | And-1 coordinates with polymerase δ to regulate nucleotide excision repair and UVB-induced skin tumorigenesis. | Nat Commun | 2025 | https://conductscience.org/library/papers/41120356 | PubMed |
| 40256842 | Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics. | J Enzyme Inhib Med Chem | 2025 | https://conductscience.org/library/papers/40256842 | PubMed |
| 39613844 | ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment. | Br J Cancer | 2025 | https://conductscience.org/library/papers/39613844 | PubMed |
| 39410888 | Non-fused Pyrimidine Derivatives as Potential Pharmacological Entities: A Review. | Curr Top Med Chem | 2025 | https://conductscience.org/library/papers/39410888 | PubMed |
| 39223250 | Cancer drug-tolerant persister cells: from biological questions to clinical opportunities. | Nat Rev Cancer | 2024 | https://conductscience.org/library/papers/39223250 | PubMed |
| 38843833 | The ribotoxic stress response drives UV-mediated cell death. | Cell | 2024 | https://conductscience.org/library/papers/38843833 | PubMed |
| 38321933 | DNA hypomethylation activates Cdk4/6 and Atr to induce DNA replication and cell cycle arrest to constrain liver outgrowth in zebrafish. | Nucleic Acids Res | 2024 | https://conductscience.org/library/papers/38321933 | PubMed |
| 37993260 | Decline of DNA damage response along with myogenic differentiation. | Life Sci Alliance | 2024 | https://conductscience.org/library/papers/37993260 | PubMed |
| 37511442 | Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/37511442 | PubMed |
| 37461317 | Metabolic clogging of mannose triggers dNTP loss and genomic instability in human cancer cells. | Elife | 2023 | https://conductscience.org/library/papers/37461317 | PubMed |
| 36768638 | The ATR Inhibitor VE-821 Enhances the Radiosensitivity and Suppresses DNA Repair Mechanisms of Human Chondrosarcoma Cells. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36768638 | PubMed |
| 36606678 | Targeting the DNA damage response for cancer therapy. | Biochem Soc Trans | 2023 | https://conductscience.org/library/papers/36606678 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ATR | 545 | PubTator's text mining | https://conductscience.org/library/genes/545 | NCBI Gene |
| CHEK1 | 1111 | PubTator's text mining | https://conductscience.org/library/genes/1111 | NCBI Gene |
| RAD51 | 5888 | PubTator's text mining | https://conductscience.org/library/genes/5888 | NCBI Gene |
| TP53BP1 | 7158 | PubTator's text mining | https://conductscience.org/library/genes/7158 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22825331
GET https://conductscience.org/api/papers/v1/22825331/references?page=2